• Fosamax
• Fosamax Bone Fractures
• Fosamax Bone Loss
• Fosamax Dead Jaw
• Fosamax Jaw Bone Loss
• Fosamax Femur Fractures
• Fosamax Lawsuit
• Fosamax Lawyers
• Fosamax Attorneys
• Fosamax Dead Jaw Lawsuit
• Fosamax Dead Jaw Lawyers
• Fosamax Osteonecrosis
• Fosamax Side Effects
• Fosamax Warning
• Contact a Lawyer

Find a Lawyer in Your State

Need Help?

• Accutane®
• Cerebral Palsy
• Darvocet®
• Denture Cream
• Depuy ASR™ Hip Implant
• Fosamax® Femur Fracture
• MiniMed Insulin Pump
• Multaq®
• Nephrogenic Systemic Fibrosis
• Paxil® Birth Defects
• Propecia®
• Shoulder Pain Pump
• Topamax®
• Truck Accident Lawyer
• Wellbutrin®
• Yaz® Birth Control

Fosamax Warning

Recent studies have raised concerns about a serious side effect of the commonly prescribed drug Fosamax (alendronate sodium). Osteonecrosis of the jaw (ONJ) is a rare bone disease shown to be a potential adverse side effect of Fosamax. ONJ causes the decay of bone tissue and may require long term drug treatment or surgery. Merck, the manufacturer of the drug, has yet to comply with an FDA request to add a prominent Fosamax warning label.

If you have developed serious bone side effects from Fosamax, you may be eligible to pursue a legal claim to get help paying for your damages. Please click here to speak with an attorney who can help or bookmark this site for future reference.

Study Prompts a Call for Fosamax Warning

Fosamax, which belongs to a class of drugs known as biophosphanates, was initially linked to ONJ after a study conducted by doctors at the Long Island Jewish Medical Center. The results of this study prompted the FDA to issue a warning to doctors about the potential risk for ONJ in patients undergoing biophosphanate therapy. Despite FDA concerns, Merck did not add a Fosamax warning label to caution users of the potential risk of osteonecrosis.

Evidence Mounts

The most recent study, quoted by United Press International in early April 2006, shows further evidence of a link between Fosamax and ONJ. At least 2,400 patients participating in the study had suffered bone damage to their jaws within the past five years. In light of this recent evidence doctors are beginning to understand the magnitude of the problem.

The Need For A Prominent Fosamax Warning

Merck''s refusal to issue a Fosamax warning has helped to keep both the medical community and the public unaware of the potential dangers posed by Fosamax. A lawsuit filed in a US District Court alleges that Merck deliberately concealed the drug''s adverse side effects from doctors and patients. The allegations stem from evidence suggesting that Merck knew that Fosamax could cause ONJ and yet still neglected to comply with the FDA''s request to add a Fosamax warning to all drug labeling.

Merck claims to have added a Fosamax warning label in July of 2005. However, this claim is misleading. Merck included the warning on page 13 of a 22-page document it distributes to pharmacies that fill Fosamax prescriptions. It is highly unlikely that the average patient or doctor would ever encounter this clandestine Fosamax warning.

For more information on Fosamax and Osteonecrosis, click here . If you have taken or are currently taking Fosamax and think you may have osteonecrosis, you may wish to speak with an experienced legal professional who can evaluate your case. Contact us to consult with a qualified attorney – FREE of charge - who can help you understand your rights.

"Women Twice as Likely to Develope Atrial Fibrillation"

A new study suggests that women taking the osteoporosis drug Fosamax are twice as likely to develop a chronic heart condition known as atrial fibrillat...

» Read More

"Conn. Woman suffers from stress fractures and suppressed bone regeneration"

A new lawsuit has been filed against Merck & Co. over its osteoporosis drug Fosamax. The suit claims the drug caused a Connecticut woman to suffer multiple stress fractures in her l...

» Read More

"Fosamax Lawsuit Cites Merck’s Negligence"

A lawsuit filed in a Florida federal court is claiming that Merck, the maker of Fosamax, was negligent in promoting its popular osteoporosis drug.

According to the complaint, Merck knew that Fosamax was defective but continuously concealed i...

» Read More